Openbookopenbook
Equity
AGY
+0.0 · +0.00%
GBX · LSE

Allergy Therapeutics(AGY) Stock Analysis | Healthcare

GBX --+0.00%
Reward43Moderate
Risk66Medium-High
75%Data
Thin -84% profit margin
Capital Destroyer
Market Cap:360.95M
ⓘ
Reward Rating
43
Moderate
Reward Assessment
75% data coverage
Bottom 25% of stocksView factors
ⓘ
Risk Rating
66
Medium-High
Risk Assessment
8 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on AGY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for AGY, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 13p.

What is Allergy Therapeutics?

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally.

AGY · Verdict

Moderate reward · elevated risk

AGY has limited near-term tailwinds — balance sheet and profitability weigh on the model output.

Based on 88% data coverage

AGY · Verdict

What’s working & what to watch

Watchouts 4

  • Balance sheet18/100

    Current ratio 1.28

  • Profitability19/100

    -73% net margin · -369% ROE

  • Cash flow20/100

    -58% free-cash-flow margin

  • Growth45/100

    Rev -8.9% CAGR · earnings +42.8%

Model-based scoring. For information only — not financial advice.

What is Allergy Therapeutics?

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 360.95M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (43)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

ANCRMicro Cap / 231M market cap
Animalcare Group Plc
Compare
HCMSmall Cap / 1.6B market cap
HUTCHMED China Ltd
Compare
EAHNano Cap / 67.4M market cap
Eco Animal Health Group Plc
Compare
Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Market Cap360.95M
P/E RatioN/A
Dividend YieldN/A
Beta0.835
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.